前沿速览015期| CAR-T治B淋 前沿览新知
01
对于既往接受过2线及以上治疗的老年和/或ECOG体能状态不佳的复发或难治性大B细胞淋巴瘤患者，Axicabtagene ciloleucel vs. 免疫化疗的获益
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy
第一作者：Lunning MA
Am J Hematol (IF=12.8). 2024 Mar 19.
全文网址：https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.27283
02
GSNOR过表达可通过强化线粒体适能增强CAR-T干性和抗肿瘤功能
GSNOR overexpression enhances CAR-T stemness and anti-tumor function by enforcing mitochondrial fitness
第一作者：Niu Q
Mol Ther (IF=12.4). 2024 Mar 27:S1525-0016(24)00211-9.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S1525-0016(24)00211-9
03
高多路单细胞成像分析揭示了与CAR-T细胞疗法临床结局相关的肿瘤免疫环境
High-multiplex single-cell imaging analysis reveals tumor immune contexture associated with clinical outcomes after CAR T cell therapy
第一作者：Jin J
Mol Ther (IF=12.4). 2024 Mar 19:S1525-0016(24)00164-3.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S1525-0016(24)00164-3
04
与年轻患者相比，CAR-T细胞疗法在70岁及以上弥漫大B细胞淋巴瘤患者中显示出相似的疗效和毒性：一项多中心队列研究
Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study
第一作者：Berning P
Hemasphere (IF=9.1). 2024 Mar 20;8(3):e54.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10953542/
05
种族和社会健康决定因素对接受CAR-T细胞治疗的侵袭性B细胞非霍奇金淋巴瘤患者的结局影响
Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-cell nHL Treated with CAR-T
第一作者：Karmali R
Blood Adv (IF=7.6). 2024 Mar 26:bloodadvances.2023011996.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023011996/515501/Impact-of-Race-and-Social-Determinants-of-Health
06
通过外周血免疫分型监测CAR19，可揭示组织特异性扩增和毒性
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity
第一作者：Hamilton MP
Blood Adv (IF=7.6). 2024 Mar 18:bloodadvances.2024012637.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024012637/515342/CAR19-monitoring-by-peripheral-blood
07
将放疗整合到CAR-T细胞治疗方案中可改善复发/难治性弥漫性大B细胞淋巴瘤患者的结局
Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
第一作者：Parikh RR
Int J Radiat Oncol Biol Phys (IF=7.0). 2024 Apr 1;118(5):1152-1158.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S0360-3016(23)00355-3
08
通过敲除ACAT1调节胆固醇代谢以改善细胞活化和增殖，从而增强CD19特异性CAR-T细胞的抗B细胞淋巴瘤活性
Modulating Cholesterol Metabolism via ACAT1 Knockdown Enhances Anti-B-Cell Lymphoma Activities of CD19-Specific Chimeric Antigen Receptor T Cells by Improving the Cell Activation and Proliferation
第一作者：Su Q
Cells (IF=6.0). 2024 Mar 21;13(6):555.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10969720/
09
描述肿瘤病灶聚集和扩散的指标及其对接受CAR-T细胞治疗的弥漫性大B细胞淋巴瘤患者预后的影响
Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy
第一作者：Dang X
Cancer Med (IF=4.0). 2024 Mar;13(6):e6991.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10952018/
10
Brexucabtagene Autoleucel (ZUMA-2) 与 Pirtobrutinib (BRUIN) 治疗既往接受过共价布鲁顿酪氨酸激酶抑制剂治疗的复发/难治性套细胞淋巴瘤患者的匹配调整间接比较
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor
第一作者：Salles G
Adv Ther (IF=3.8). 2024 Mar 18.
全文网址：https://link.springer.com/article/10.1007/s12325-024-02822-z
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.4-1 valid until 2026.4
供稿与审核：临床开发与医学部